title: [Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice].
abstract: Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S. aureus pneumonia following A/California/04/2009 (H1N1) influenza virusinfection. Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by ≥ 2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.
authors.forename: I A
authors.initials: IA
authors.lastname: Leneva
authors.forename: I N
authors.initials: IN
authors.lastname: Falynskova
authors.forename: E I
authors.initials: EI
authors.lastname: Leonova
authors.forename: I T
authors.initials: IT
authors.lastname: Fedyakina
authors.forename: N R
authors.initials: NR
authors.lastname: Makhmudova
authors.forename: E A
authors.initials: EA
authors.lastname: Osipova
authors.forename: L N
authors.initials: LN
authors.lastname: Lepekha
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhailova
authors.forename: V V
authors.initials: VV
authors.lastname: Zverev
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D058491:Bacterial Load / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D060085:Coinfection; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005260:Female; D007211:Indoles / Q000494:pharmacology*; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000254:growth & development; D008168:Lung / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000821:virology; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality / Q000473:pathology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D016019:Survival Analysis; D019562:Viral Load / Q000187:drug effects; D013440:Sulfides
chemical_list: D000998:Antiviral Agents; D007211:Indoles; C086979:umifenovir; D013440:Sulfides